Table 1.
|
Week of Study |
|
|||||
---|---|---|---|---|---|---|---|
0 | 4 | 8 | 9 | 10 | 12 | p-valueb | |
Squat, kg |
|
|
|
|
|
|
|
Placebo |
145.2 ± 10.2 |
151.6 ± 11.0 |
156.4 ± 11.6 |
150.7 ± 10.4 |
147.2 ± 10.7 |
151.3 ± 10.3 |
|
ATP |
146.1 ± 5.8 |
155.2 ± 7.7 |
160.7 ± 7.6 |
159.0 ± 6.1# |
158.6 ± 6.9# |
165.3 ± 8.3# |
<0.001 |
Bench Press, kg |
|
|
|
|
|
|
|
Placebo |
115.2 ± 9.4 |
119.3 ± 9.4 |
121..4 ± 9.3 |
113.4 ± 7.2 |
115.7 ± 8.0 |
119.3 ± 8.7 |
|
ATP |
117.2 ± 5.5 |
122.1 ± 5.0 |
124.5 ± 5.2 |
120.0 ± 4.8 |
121.2 ± 5.5 |
124.2 ± 5.4 |
0.65 |
Deadlift, kg |
|
|
|
|
|
|
|
Placebo |
169.8 ± 11.0 |
177.0 ± 10.7 |
182.5 ± 10.7 |
173.2 ± 10.8 |
174.8 ± 8.1 |
182.0 ± 9.2 |
|
ATP |
176.2 ± 4.9 |
189.2 ± 5.9 |
200.3 ± 7.4# |
193.4 ± 6.4# |
193.8 ± 8.3# |
205.2 ± 6.9# |
0.002 |
Total Strength, kg |
|
|
|
|
|
|
|
Placebo |
430.2 ± 28.1 |
448.0 ± 28.9 |
460.2 ± 29.6 |
437.3 ± 26.1 |
437.6 ± 25.1 |
452.6 ± 25.9 |
|
ATP |
439.4 ± 14.9 |
466.5 ± 17.1 |
485.6 ± 18.1# |
472.4 ± 15.2# |
473.6 ± 18.3# |
494.7 ± 17.9# |
<0.001 |
Wingate Peak Power, Watts |
|
|
|
|
|
|
|
Placebo |
882.2 ± 54.1 |
930.3 ± 55.7 |
985.3 ± 64.7 |
922.9 ± 61.9 |
939.9 ± 65.7 |
977.4 ± 66.5 |
|
ATP |
882.8 ± 27.0 |
960.9 ± 36.1 |
1003.5 ± 40.4 |
964.2 ± 38.0 |
974.7 ± 39.8 |
1011.9 ± 42.4 |
0.48 |
Vertical Jump power, Watts |
|
|
|
|
|
|
|
Placebo |
5318 ± 410 |
5711 ± 439 |
5918 ± 443 |
5697 ± 436 |
5626 ± 431 |
5932 ± 452 |
|
ATP | 5185 ± 203 | 5618 ± 213 | 5954 ± 202# | 5838 ± 218# | 5827 ± 208# | 5981 ± 207# | <0.001 |
aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise) and n = 10 placebo supplemented participants.
bProbability of treatment by time difference between the placebo and the ATP treatments over the 12-week study. The mixed model ANOVA in SAS® was used with the main effects of treatment, time and treatment by time, with the value for week 0 used as a covariate.
#Significantly different than corresponding placebo, t-test (p < 0.05).